EARLY AND COST EFFECTIVE PREDICTION OF TREATMENT OUTCOME WITH IFNA2B OR PEG-IFNA2B PLUS RIBAVIRIN COMPUTING INFECTED CELLS DYNAMICS BY ALT AND HCV-RNA DECLINE DURING THE FIRST MONTH